Department of Gynaecology, Aarhus University Hospital, 99, Palle Juul-Jensens Boulevard, DK-8200, Aarhus N, Denmark; Aarhus University, Faculty of Health, Institute of Clinical Medicine, 99, Palle Juul-Jensens Boulevard, DK-8200, Aarhus N, Denmark; University of Southern Denmark, Faculty of Health Sciences, Clinical Institute, 19, JB Winsloews Vej, DK-5000, Odense, Denmark.
Department of Gynaecology, Copenhagen University Hospital, Rigshospitalet. 9, Blegdamsvej, DK-2100, Copenhagen, Denmark.
Eur J Cancer. 2020 Mar;128:47-56. doi: 10.1016/j.ejca.2019.12.020. Epub 2020 Mar 5.
Lately, the safety of minimally invasive surgery (MIS) in the treatment of cervical cancer (CC) has been questioned. This study aimed to evaluate the risk of recurrence and survival after a nationwide adoption of robotic MIS for the treatment of early-stage CC in Denmark.
Population-based data on all Danish women with early-stage CC, who underwent radical hysterectomy January 1st 2005-June 30th 2017 were retrieved from the Danish Gynecologic Cancer Database and enriched with follow-up data on recurrence, death and cause of death. The cohort was divided into two groups according to the year of robotic MIS introduction at each cancer centre. Chi-squared or Fischer test, the Kaplan Meier method and multivariate Cox regression were used for comparison between groups.
One thousand one hundred twenty-five patients with CC were included; 530 underwent surgery before (group 1) and 595 underwent surgery after (group 2) the introduction of robotic MIS. The 5-year rate of recurrence was low: 8.2% and 6.3% (p = 0.55) in group 1 and 2, respectively. In adjusted analyses, this corresponded to a five-year disease-free survival, hazard ratio (HR) 1.23 [95% confidence interval (CI) 0.79-1.93]. No difference in site of recurrence (P = 0.19) was observed. The cumulative cancer-specific survival was 94.1% and 95.9% (P = 0.10) in group 1 and 2, respectively, corresponding to a HR 0.60 [95% CI 0.32-1.11] in adjusted analyses.
In this population-based cohort study, the Danish nationwide adoption of robotic MIS for early-stage CC was not associated with increased risk of recurrence or reduction in survival outcomes.
最近,微创外科(MIS)治疗宫颈癌(CC)的安全性受到了质疑。本研究旨在评估丹麦全国范围内采用机器人 MIS 治疗早期 CC 的复发和生存风险。
从丹麦妇科癌症数据库中检索了 2005 年 1 月 1 日至 2017 年 6 月 30 日期间所有接受根治性子宫切除术的丹麦早期 CC 女性的基于人群的数据,并通过复发、死亡和死因的随访数据进行了补充。根据每个癌症中心采用机器人 MIS 的时间,将队列分为两组。使用卡方检验或 Fischer 检验、Kaplan-Meier 方法和多变量 Cox 回归对两组之间进行比较。
共纳入 1125 例 CC 患者;530 例在机器人 MIS 引入前(组 1)进行手术,595 例在机器人 MIS 引入后(组 2)进行手术。5 年复发率较低:组 1 和 2 分别为 8.2%和 6.3%(p=0.55)。在调整后的分析中,这相当于 5 年无病生存率,风险比(HR)为 1.23[95%置信区间(CI)0.79-1.93]。未观察到复发部位的差异(P=0.19)。组 1 和 2 的累积癌症特异性生存率分别为 94.1%和 95.9%(P=0.10),调整后的分析中 HR 为 0.60[95%CI 0.32-1.11]。
在这项基于人群的队列研究中,丹麦全国范围内采用机器人 MIS 治疗早期 CC 与复发风险增加或生存结果降低无关。